- All sections
- C - Chemistrymetallurgy
- C07F - Acyclic, carbocyclic, or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
- C07F 9/59 - Hydrogenated pyridine rings
Patent holdings for IPC class C07F 9/59
Total number of patents in this class: 142
10-year publication summary
13
|
16
|
14
|
20
|
11
|
14
|
9
|
5
|
5
|
2
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Bristol-myers Squibb Company | 4848 |
9 |
Allergan, Inc. | 2371 |
6 |
Vertex Pharmaceuticals Incorporated | 1591 |
6 |
SRX Cardio, LLC | 21 |
5 |
Glaxosmithkline Intellectual Property (no.2) Limited | 282 |
4 |
Board of Regents, The University of Texas System | 5704 |
4 |
Celgene Corporation | 1418 |
4 |
ChemoCentryx, Inc. | 389 |
4 |
Novartis AG | 11011 |
3 |
Northwestern University | 3323 |
3 |
AM Chemicals LLC | 10 |
3 |
KemPharm, Inc. | 32 |
3 |
Sarepta Therapeutics, Inc. | 370 |
3 |
University of Manitoba | 451 |
3 |
Recurium IP Holdings, LLC | 131 |
3 |
Zevra Therapeutics, Inc. | 94 |
3 |
Centre National de La Recherche Scientifique | 10227 |
2 |
Takeda Pharmaceutical Company Limited | 2693 |
2 |
Amyris, Inc. | 375 |
2 |
Cardioxyl Pharmaceuticals, Inc. | 48 |
2 |
Other owners | 68 |